M. S. Czuczman

Medicine · Health Sciences

27h-index7.3kcitations89works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(71), Chronic Lymphocytic Leukemia Research(38), Monoclonal and Polyclonal Antibodies Research(24), Lung Cancer Treatments and Mutations(15), CAR-T cell therapy research(12)

Publications89 total

Novel induced-mesenchymal stem cells (i-MSCS) attenuate severity of ards in septic sheep
Cytotherapy·2021· 1 cited
PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA
HemaSphere·2019Open Access
AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R<sup>2</sup>) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS
Hematological Oncology·2019· 11 citedOpen Access
POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R<sup>2</sup>) VS RITUXIMAB/PLACEBO (AUGMENT)
Hematological Oncology·2019· 2 cited
PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)
HemaSphere·2019Open Access
AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R<sup>2</sup>) THAN RITUXIMAB/PLACEBO
Hematological Oncology·2019· 1 cited
ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R<sup>2</sup>‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma
Hematological Oncology·2019· 84 cited
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
Annals of Oncology·2015· 90 citedOpen Access
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
Leukemia·2015· 149 cited
Anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells significantly mediate rituximab sensitive and resistant burkitt lymphoma (BL) regression and improve survival in human BL xenografted NSG mice
Cytotherapy·2014· 5 cited
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
Annals of Oncology·2013· 120 citedOpen Access
Final Results of a Phase I Study of the Anti-CD79b Antibody-Drug Conjugate DCDS4501A (Polatuzumab Vedotin) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 4400
2013· 1 cited
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
Annals of Oncology·2012· 63 citedOpen Access
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
Haematologica·2011· 165 citedOpen Access
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
Annals of Oncology·2011· 392 citedOpen Access
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
British Journal of Cancer·2010· 129 citedOpen Access
611 Bcl-2 family protein expression in navitoclax-treated patients (pts) with lymphoid malignancies
European Journal of Cancer Supplements·2010
Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R).
Journal of Clinical Oncology·2010· 5 cited
Efficacy of combination of rituximab (R), obatoclax (O), and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL).
Journal of Clinical Oncology·2010· 2 cited
Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).
Journal of Clinical Oncology·2010· 26 cited
page 1 of 5Next →

Frequent Co-authors

A.J. Grillo-López(9), Thomas E. Witzig(8), Philip L. McCarthy(7), Francisco J. Hernandez‐Ilizaliturri(6), Peter McLaughlin(5), Leo I. Gordon(5), Julie M. Vose(5), Zale P. Bernstein(5), Asher Chanan‐Khan(5), Theresa Hahn(5), Christine A. White(4), Pier Luigi Zinzani(4), Craig B. Reeder(4), Jonathan Polikoff(4), Arif Alam(4), John P. Leonard(4), Mustafa Beneklı(4), B Bambach(4), Brian K. Link(3), Donald Klippenstein(3)